Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical
Biora Therapeutics Inc (NASDAQ: BIOR) announced that the FDA has cleared the company's Investigational New Drug (IND) application for BT-600, a drug/device combination for moderate to
Data from nine abstracts to be presented, including real-world outcomes of Epidiolex® (cannabidiol) in treatment-resistant focal epilepsiesPresentations include data on U.S. caregiver-reported seizure and
– Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for
Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation
GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced new data to be presented at the American Epilepsy Society (AES) annual meeting in Orlando,
Palvella Received $5 Million Upfront Payment QTORIN™ rapamycin has Potential to be First FDA Approved Therapy and Standard of Care in the U.S. for an Estimated more than 30,000 Diagnosed Patients with
The collaboration between SciSparc and Clearmind continues to yield positive results in its obesity and metabolic disorder programTEL AVIV, Israel, Dec. 01, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company"